GlaxoSmithKline LLC 2024-06-12 Health moderate FDA
Health · FDA · Recall #FDA-D-0544-2024
Tivicay PD (dolutegravir) 5mg Tablets for Oral Suspension, 60-count bottles, Each carton… Recall
Issued June 12, 2024 · GlaxoSmithKline LLC
In June 2024, GlaxoSmithKline LLC recalled the Tivicay PD (dolutegravir) 5mg Tablets for Oral Suspension, 60-count bottles, Each carton…, a moderate health recall reported by the FDA.
Compiled by Maya Ellison, RecallCheckr
What this means for you
Labeling: Incorrect Lot and/or Expiration Date: The carton has incorrect expiration of 2026-MAY*, whereas the correct expiration date, which is on the tablet bottle label, is 2025-APR.
What you should do
- 1 Stop using Tivicay PD (dolutegravir) 5mg Tablets for Oral Suspension, 60-count bottles, Each carton… right away.
- 2 Set it aside where it won't be used by mistake.
- 3 Contact GlaxoSmithKline LLC to arrange your voluntary. See the official notice below for contact details.
- 4 Keep the product until your remedy is fully processed. You may need it.
Official remedy (Voluntary):
Recall details
- Brand
- GlaxoSmithKline LLC
- Category
- Health
- Recall date
- June 12, 2024
- Units affected
- Not reported
- Sold at
- Nationwide within the United States
- Recall number
- FDA-D-0544-2024
- Made in
- United States
- Issuing agency
- FDA
In context
- GlaxoSmithKline LLC has 3 recalls in our database.
- We're tracking 3,576 Health recalls in our database.
- This is the 737th Health recall we've logged in 2024.